Ishiguro, Hiroshi http://orcid.org/0000-0002-9859-5932
Ohno, Shinji
Yamamoto, Yutaka
Takao, Shintaro
Sato, Nobuaki
Fujisawa, Tomomi
Kadoya, Takayuki
Kuroi, Katsumasa
Bando, Hiroko
Teramura, Yasufumi
Iwata, Hiroji
Tanaka, Shiro
Toi, Masakazu
Funding for this research was provided by:
Japan Breast Cancer Research Group (JBCRG12, JBCRG15)
Article History
Received: 14 June 2018
Accepted: 3 February 2019
First Online: 7 February 2019
Compliance with ethical standards
:
: H. Ishiguro received research Grants from NipponKayaku and Japan Breast Cancer Research Group. S. Ohno serves as a consultant to Chugai, AstraZeneca, Novartis, Sanofi, Pfizer, Taiho, Eisai, and Kyowa Hakko Kirin. Y. Yamamoto reports personal fees from Nippon Kayaku during the conduct of the study, personal fees from Chugai Pharmaceutical, AstraZeneca, Novartis Pharma, KyowaHakkoKirin, Esai, Pfizar, DaiichiSankyo, Sysmex, Grants from MSD, Puma, Lilly, and personal fees from Taiho, Takeda, Sanofi, and Ono Yakuhin outside the submitted work. N. Sato received lecture fees from Chugai, AstraZeneca, Eisai, Pfizer, and Taiho. S Tanaka serves as a consultant to Pharmaceuticals and Medical Devise Agency, DeNA Life Science, Boehringer Ingelheim, Public Health Research Foundation, Japan Breast Cancer Research Group and Satt, and received research Grants from the Project Promoting Clinical Trials for Development of New Drugs (17lk0201061h0002) of Japan Agency for Medical Research and Development (AMED), Japanese Ministry of Health Labor and Welfare, and Japanese Ministry of Education, Science and Technology. M. Toi received lecture fees from NipponKayaku, Kyowa Hakko Kirin, Takeda, Taiho, Chugai, Novartis, Eisai, Pfizer, and AstraZeneca, and received research Grants from NipponKayaku, Taiho, Chugai, Novartis, Eisai, Pfizer, and AstraZeneca. S. Takao, T. Fujisawa, T. Kadoya, K. Kuroi, H. Bando, Y. Teramura, and H. Iwata have no conflict of interest.